This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Keratinocyte Growth Factor to Prevent Acute GVHD

This study has been completed.
Information provided by:
FDA Office of Orphan Products Development Identifier:
First received: February 26, 2002
Last updated: March 24, 2015
Last verified: January 2002
This is a study to determine the safety and efficacy of keratinocyte growth factor (KGF) to prevent acute graft-versus-host disease (GVHD) in patients undergoing allogeneic bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplantation.

Condition Intervention Phase
Graft-vs-Host Disease Drug: Recombinant Human Keratinocyte Growth Factor (rHuKGF) Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double
Primary Purpose: Prevention
Official Title: Phase I/II Trial of Keratinocyte Growth Factor (rHuKGF) to Prevent Acute GVHD in 6/6 HLA=BMT Recipients

Resource links provided by NLM:

Further study details as provided by FDA Office of Orphan Products Development:

Estimated Enrollment: 72
Study Start Date: September 2001
Estimated Study Completion Date: August 2003
Detailed Description:

GVHD remains the major complication of allogeneic BM transplantation and is initiated during the conditioning of the recipient for transplant when the host tissues are damaged. Research has demonstrated that the gastrointestinal (GI) tract is a critical organ in GVHD pathophysiology. Agents that protect the GI tract may provide prophylaxis against the cytokine cascade and can lead to a reduced incidence and severity of GVHD. KGF is a protein that stimulates the growth of epithelial cells including those of the GI tract. KGF can protect the GI tract, prevent GVHD, and preserve donor T-cell function.

Patients will receive standard GVHD prophylaxis in addition to the study drug. Overall GVHD will be graded weekly during the first 2 months after transplant, then every other week to Day 100. Response to therapy will be measured through the use of severity indices, physical exam, and laboratory serum values.


Ages Eligible for Study:   3 Years to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Diagnosis of a hematological malignancy, including myelodysplastic syndromes.
  • Eligible for cyclophosphamide and total body irradiation conditioning therapy or busulphan and cyclophosphamide conditioning therapy.
  • Must have a 6/6 human leukocyte antigens (HLA)-matched family member donor.
  • Women must be post-menopausal, sterile, or using effective contraception for 1 month before, during, and for 2 months after study.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

Exclusion criteria:

  • T-cell depletion for GVHD prophylaxis.
  • Active hepatitis.
  • Pre-existent inflammatory bowel disease requiring active therapy.
  • Active uncontrolled infection.
  • Prior bone marrow or peripheral blood stem cell (PBSC) transplantation.
  • Documented hypersensitivity to rHuKGF.
  • Prior enrollment to a study of rHuKGF.
  • HIV-positive.
  • Pregnant or nursing.
  • Active chronic skin disease requiring therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00031148

United States, Michigan
University of Michigan Cancer Center
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
FDA Office of Orphan Products Development
  More Information Identifier: NCT00031148     History of Changes
Other Study ID Numbers: FD-R-2021-01
Study First Received: February 26, 2002
Last Updated: March 24, 2015

Keywords provided by FDA Office of Orphan Products Development:
Keratinocyte growth factor
Bone Marrow Transplantation
Hematopoietic Stem Cell Transplantation
HLA Antigens
Transplantation, Homologous
Recombinant Proteins

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017